OKYO Pharma: Chairman-linked entity buys 210,000; total 10,382,677

OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ.

Rhea-AI Filing Summary

OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ. Following this purchase, his total holding is 10,382,677 shares. The news announcement was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.

Insights

Corporate governance analyst

Insider‑affiliated purchase disclosed; administrative and informational.

OKYO Pharma disclosed that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, acquired 210,000 shares on NASDAQ, bringing his total to 10,382,677 shares. This is an informational update via a furnished exhibit.

The event indicates increased holdings by an insider‑affiliated entity; however, the disclosure does not provide pricing, rationale, or implications beyond the updated stake. It does not alter capital structure through issuance.

The announcement is furnished as Exhibit 99.1 and “shall not be deemed filed,” which limits potential liabilities under Section 18. Subsequent company filings may provide additional context.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OKYO (OKYO) disclose in its Form 6-K?

OKYO reported that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, acquired 210,000 ordinary shares on NASDAQ.

How many OKYO shares were acquired and what is the new total holding?

The acquisition was 210,000 shares, bringing the total holding to 10,382,677 shares.

Who is Panetta Partners Limited in relation to OKYO?

Panetta Partners Limited is an entity in which Gabriele Cerrone, OKYO’s Executive Chairman, has a beneficial interest.

Where was the acquisition of OKYO shares executed?

The shares were acquired on NASDAQ.

Is the news announcement part of the official record or just furnished?

It was furnished as Exhibit 99.1 and is not deemed “filed” under Section 18 of the Exchange Act.

What is the exhibit number and date for the announcement?

The announcement is Exhibit 99.1, dated October 16, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/16/2025 - 12:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 2025

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 16, 2025, OKYO Pharma LTD (the “Company”) issued this 6K announcing, it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 210,000 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,382,677 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: October 16, 2025	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated October 16, 2025

4